1 Global state: 1. Not improved or worsened ‐ short term |
1 |
95 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.46 [1.51, 3.99] |
2 Global state: 2. Relapse |
9 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
2.1 short term |
3 |
376 |
Risk Ratio (M‐H, Fixed, 95% CI) |
6.76 [3.37, 13.54] |
2.2 medium term |
6 |
850 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.04 [2.81, 5.81] |
2.3 long term |
3 |
510 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.70 [1.44, 2.01] |
3 Leaving study early ‐ any reasons ‐ medium term |
1 |
374 |
Risk Difference (M‐H, Fixed, 95% CI) |
0.01 [‐0.04, 0.06] |
4 Mental state: Not improved or worsened |
1 |
12 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.60, 1.66] |
5 Sensitivity analysis: HIGH DOSE vs LOW DOSE ‐ outcome relapse |
7 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
5.1 high dose (>500mg/day) |
1 |
42 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.07, 14.95] |
5.2 low dose (<500mg/day) |
6 |
934 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.13 [1.79, 2.53] |
6 Sensitivity analysis: DIAGNOSTIC CRITERIA vs NO‐DIAGNOSTIC CRITERIA ‐ outcome relapse |
10 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
6.1 diagnostic criteria |
1 |
374 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.67 [1.42, 1.97] |
6.2 no diagnostic criteria |
9 |
637 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.53 [2.83, 7.25] |